GH · Guardant Health, Inc.
$157.38
-1.04% last session
End-of-day data · close of 2026-09-11
Market cap
$21B
Enterprise value
$22B
Trailing P/E
—
Forward P/E
-359.5
Dividend yield
—
Beta
1.58
Avg volume
3M
Employees
2K
Daily Change %
-1.04%
5 Days Change
0.85%
10 Days Change
2.36%
30 Days Change
-1.40%
60 Days Change
1.71%
Month to Day Change
-0.99%
Year to Day Change
59.37%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — GH
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-09
Latest call per bank · past 12 months
UBS
Buy$225
+41.5% vs priceMorgan Stanley
Overweight$185
+16.3% vs priceRBC Capital
Outperform$200
+25.8% vs priceJP Morgan
Overweight$195
+22.6% vs priceBarclays
Overweight$200
+25.8% vs priceCitigroup
Buy$215
+35.2% vs priceBank of America
Buy$190
+19.5% vs priceGoldman Sachs
Buy$165
+3.8% vs priceWells Fargo
Overweight$125
-21.4% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-09 | UBS | Maintains | Buy | $175 → $225 |
| 2026-09-08 | Rothschild & Co | Initiates | Buy | $0.00 → $203 |
| 2026-09-02 | BTIG | Reiterates | Buy | $195 |
| 2026-08-04 | Piper Sandler | Maintains | Overweight | $135 → $193 |
| 2026-08-04 | Stephens & Co. | Maintains | Overweight | $170 → $195 |
| 2026-08-04 | Morgan Stanley | Maintains | Overweight | $175 → $185 |
| 2026-08-03 | Stifel | Maintains | Buy | $130 → $180 |
| 2026-07-31 | RBC Capital | Maintains | Outperform | $185 → $200 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 46 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 1.6% below the 50-day MA ($159.85).
- Price vs 200-day MA: Trading 32.7% above the 200-day MA ($118.58).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-1.19) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($54.79) and high ($170.92).
GH Price Chart
Loading chart for GH…
Fundamentals
About Guardant Health, Inc.
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
More in Diagnostics & Research
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.